UK government to update legal definition of gene therapies to cover synthetic technologies
On 19 November 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) confirmed government plans to update the legal definition of gene therapy medicinal products in the United Kingdom. Gene therapy medicinal products are treatments that work by modifying genetic material. The update will amend the Human Medicines Regulations 2012 so that newer synthetic gene therapies and genome-editing techniques fit into the UK's regulatory rules. A public consultation on the plan closed on 22 June 2026, with 83% of respondents backing the update. For patients and the public, these regulatory definitions determine how regulators evaluate the safety, quality, and efficacy of new biological medicines before they reach clinics. The MHRA stated that standards for approving medicines will remain unchanged, while medicines that are already licensed will not need to be reclassified. The reform is intended to give drug developers clear rules for newer technologies that did not exist when the previous definitions were established in 2007.
What was announced
The Medicines and Healthcare products Regulatory Agency (MHRA), working with the Department of Health in Northern Ireland, announced amendments to the Human Medicines Regulations 2012. These changes update the legal classification for gene therapy medicinal products, often shortened to GTMPs.
Under the new approach, a product will be classified as a gene therapy based on whether its active substance contains recombinant or synthetic nucleic acid that undergoes transcription or translation, or whether its mechanism of action relies on sequence-specific genome editing. Recombinant or synthetic nucleic acids are lab-made genetic codes designed to instruct cells how to build proteins.
Following a six-week consultation that ran from 11 May 2026 to 22 June 2026, the proposal received support from 83% of respondents. The announcement was made during the DIA-MHRA Global Summit in London.
What it means
Current rules date back to 2007, when advanced therapies relied on a narrower selection of technologies. Since then, researchers have developed therapies using synthetic genetic material and newer genome-editing platforms. Many of these products do not match the old categories in the regulations.
The updated definition brings these newer technologies under the UK's established regulatory system for Advanced Therapy Medicinal Products (ATMPs). Developers will have clearer instructions regarding which legal path their products must follow during development and licensing.
Standards for safety, quality, and efficacy will remain unchanged. In addition, treatments that have already gained approval will keep their current classifications, meaning manufacturers will not have to reapply under the new system.
What the announcement does not tell us
The announcement does not state when the updated regulations will take effect. The proposals remain subject to international notification procedures and UK parliamentary approval, but the government provided no timetable or target dates for those steps.
Furthermore, the government did not list which specific synthetic therapies or clinical candidates will fall under the new definition once it becomes law. It also did not disclose details on how many total respondents took part in the consultation, publishing only the percentage who supported the plan.
How this was written
This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is gov.uk: Medicines and Healthcare products Regulatory Agency’s own. Always check the original before acting on anything here.
Proposed changes will provide clearer regulatory pathway for certain synthetic gene therapies, supporting life sciences innovation while maintaining safety.
Opens www.gov.uk
More from gov.uk: Medicines and Healthcare products Regulatory Agency
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.